S&P 500   5,015.60 (+0.09%)
DOW   37,961.30 (+0.49%)
QQQ   420.93 (-0.59%)
AAPL   165.98 (-0.63%)
MSFT   403.65 (-0.15%)
META   494.29 (-1.50%)
GOOGL   154.50 (-0.97%)
AMZN   177.59 (-0.91%)
TSLA   148.60 (-0.89%)
NVDA   837.10 (-1.13%)
AMD   151.34 (-2.41%)
NIO   3.86 (-3.50%)
BABA   68.58 (-0.44%)
T   16.34 (+0.06%)
F   12.15 (+0.75%)
MU   109.95 (-1.77%)
GE   152.24 (-0.46%)
CGC   7.89 (+0.77%)
DIS   111.98 (-0.40%)
AMC   2.85 (-2.40%)
PFE   25.43 (+0.16%)
PYPL   62.14 (+0.06%)
XOM   119.73 (+1.02%)
S&P 500   5,015.60 (+0.09%)
DOW   37,961.30 (+0.49%)
QQQ   420.93 (-0.59%)
AAPL   165.98 (-0.63%)
MSFT   403.65 (-0.15%)
META   494.29 (-1.50%)
GOOGL   154.50 (-0.97%)
AMZN   177.59 (-0.91%)
TSLA   148.60 (-0.89%)
NVDA   837.10 (-1.13%)
AMD   151.34 (-2.41%)
NIO   3.86 (-3.50%)
BABA   68.58 (-0.44%)
T   16.34 (+0.06%)
F   12.15 (+0.75%)
MU   109.95 (-1.77%)
GE   152.24 (-0.46%)
CGC   7.89 (+0.77%)
DIS   111.98 (-0.40%)
AMC   2.85 (-2.40%)
PFE   25.43 (+0.16%)
PYPL   62.14 (+0.06%)
XOM   119.73 (+1.02%)
S&P 500   5,015.60 (+0.09%)
DOW   37,961.30 (+0.49%)
QQQ   420.93 (-0.59%)
AAPL   165.98 (-0.63%)
MSFT   403.65 (-0.15%)
META   494.29 (-1.50%)
GOOGL   154.50 (-0.97%)
AMZN   177.59 (-0.91%)
TSLA   148.60 (-0.89%)
NVDA   837.10 (-1.13%)
AMD   151.34 (-2.41%)
NIO   3.86 (-3.50%)
BABA   68.58 (-0.44%)
T   16.34 (+0.06%)
F   12.15 (+0.75%)
MU   109.95 (-1.77%)
GE   152.24 (-0.46%)
CGC   7.89 (+0.77%)
DIS   111.98 (-0.40%)
AMC   2.85 (-2.40%)
PFE   25.43 (+0.16%)
PYPL   62.14 (+0.06%)
XOM   119.73 (+1.02%)
S&P 500   5,015.60 (+0.09%)
DOW   37,961.30 (+0.49%)
QQQ   420.93 (-0.59%)
AAPL   165.98 (-0.63%)
MSFT   403.65 (-0.15%)
META   494.29 (-1.50%)
GOOGL   154.50 (-0.97%)
AMZN   177.59 (-0.91%)
TSLA   148.60 (-0.89%)
NVDA   837.10 (-1.13%)
AMD   151.34 (-2.41%)
NIO   3.86 (-3.50%)
BABA   68.58 (-0.44%)
T   16.34 (+0.06%)
F   12.15 (+0.75%)
MU   109.95 (-1.77%)
GE   152.24 (-0.46%)
CGC   7.89 (+0.77%)
DIS   111.98 (-0.40%)
AMC   2.85 (-2.40%)
PFE   25.43 (+0.16%)
PYPL   62.14 (+0.06%)
XOM   119.73 (+1.02%)
NASDAQ:KITE

(KITE) (KITE) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$179.79
$179.79
50-Day Range
N/A
52-Week Range
$39.82
$179.99
Volume
N/A
Average Volume
1.65 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
KITE stock logo

About (KITE) Stock (NASDAQ:KITE)

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).

KITE Stock News Headlines

Don’t expose yourself to stocks during the week
The S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.
Go fly a kite ... for mental health
Don’t expose yourself to stocks during the week
The S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.
See More Headlines
Receive KITE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (KITE) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2017
Today
4/18/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:KITE
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Arie S. Belldegrun
    Executive Chairman of the Board, President, Chief Executive Officer, Founder
  • Paul L. Jenkinson
    Chief Financial Officer
  • Cynthia M. Butitta
    Chief Operating Officer
  • David Chang M.D. Ph.D.
    Executive Vice President - Research and Development, Chief Medical Officer
  • Helen S. Kim
    Executive Vice President - Business Development
  • Timothy L. Moore
    Executive Vice President - Technical Operations
  • Christine Cassiano
    Senior Vice President - Corporate Communications and Investor Relations

  • Bio & Compensation - 
  • Jian Irish Ph.D.
    Senior Vice President - Supply Chain

  • Bio & Compensation - 
  • Jeffrey Wiezorek M.D.
    Senior Vice President - Clinical Development
  • Shawn Cline Tomasello
    Chief Commercial Officer

KITE Stock Analysis - Frequently Asked Questions

How were (KITE)'s earnings last quarter?

(KITE) (NASDAQ:KITE) posted its earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, beating analysts' consensus estimates of ($1.75) by $0.05. The biopharmaceutical company earned $4.90 million during the quarter, compared to analysts' expectations of $5.74 million. The company's revenue for the quarter was up .0% compared to the same quarter last year. During the same period last year, the business posted ($0.54) earnings per share.

What other stocks do shareholders of (KITE) own?
This page (NASDAQ:KITE) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners